Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmuno. Sys Regulatory News (IDH)

Share Price Information for Immuno. Sys (IDH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 225.00
Bid: 210.00
Ask: 240.00
Change: 0.00 (0.00%)
Spread: 30.00 (14.29%)
Open: 225.00
High: 230.00
Low: 230.00
Yest. Close: 225.00
IDH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Launch of IDS-iSYS InaKtif MGP assay

Wed, 1st Mar 2017 10:01

RNS Number : 2054Y
Immunodiagnostic Systems Hldgs PLC
01 March 2017

Immunodiagnostic Systems Holdings plc.

1 March 2017

Launch of IDS-iSYS InaKtif MGP assay - new assay in the IDS CKD-MDB portfolio

Immunodiagnostic Systems Holdings plc (IDS), a specialist producer of manual and automated diagnostic testing kits and instruments for the clinical market, has launched the IDS-iSYS InaKtif MGP assay in the European market. This is a fully automated CLIA assay for use with plasma samples on the IDS-iSYS Automated System.

The launch of the IDS-iSYS InaKtif MGP assay is the first vascular calcification addition to the IDS Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD) portfolio. IDS believes this assay is the first fully automated solution for the measurement of InaKtif MGP.

The IDS-iSYS InaKtif MGP assay measures a patient's inactive dephosphorylated-uncarboxylated (dp-uc) isoform of Matrix Gla-Protein (MGP) and offers clinicians an easy way to assess the vitamin K status in the arterial vessel wall. A rise of the inactive form of MGP (dp-ucMGP) reflects a vitamin K deficiency in the vasculature. Insufficient vitamin K status may result in an increased risk of vascular calcification, which is the leading cause of death in patients with CKD-MBD.

Chronic kidney disease (CKD) is an increasing public health issue, with it estimated to be prevalent in 8 to 16% of the global population.

The global market size for MGP testing is estimated to be approximately US$10 million.

For further information:

Immunodiagnostic Systems Holdings plc Tel: +44 (0) 191 519 0660

Patricio Lacalle, Chief Executive Officer

Paul Martin, Group Finance Director

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel

Oliver Jackson

This information is provided by RNS
The company news service from the London Stock Exchange
Date   Source Headline
31st Mar 202011:00 amRNSDirector/PDMR Shareholding
21st Feb 20204:11 pmRNSDirector/PDMR Shareholding
21st Feb 20209:11 amRNSDirector/PDMR Shareholding
20th Feb 20204:49 pmRNSDirector/PDMR Shareholding
22nd Nov 20194:35 pmRNSHalf-year Report

Login to your account

Don't have an account? Click here to register.